Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

New approaches to the measurement of cognition in schizophrenia include the use of tasks from experimental cognitive psychology to examine the integrity of specific cognitive systems and the application of these tasks in noninvasive neuroimaging (e.g., functional magnetic resonance imaging [fMRI]) studies that directly measure the effects of drugs on cognition-related brain activity. These approaches offer many advantages, including the isolation of specific cognitive systems that may be conserved across species; controlling for the confounding effects of generalized performance deficits such as poor motivation, sedation, and so on; and providing a direct translational bridge from studies using animal models of cognition to patient-based research using fMRI. These developments have the potential to transform the early human phases of drug development and streamline the decision making at this critical point in the process. As was the case for the Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative, optimizing the application of cognitive neuroscience to new drug development will require a major commitment by multiple investigators to task development and a thorough psychometric evaluation of both behavioral and neuroimaging measures.

Original languageEnglish (US)
Pages (from-to)810-815
Number of pages6
JournalSchizophrenia Bulletin
Volume31
Issue number4
DOIs
StatePublished - Oct 2005

Fingerprint

Cognition
Schizophrenia
Neuroimaging
Pharmaceutical Preparations
Magnetic Resonance Imaging
Experimental Psychology
Therapeutics
Research
Psychometrics
Motivation
Decision Making
Animal Models
Research Personnel
Cognitive Neuroscience
Brain

Keywords

  • Cognitive enhancement
  • Cognitive neuroscience
  • Cognitive psychology
  • Neuropsychology
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

@article{438ba15ccc4f4c35add1ff13c999767d,
title = "Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia",
abstract = "New approaches to the measurement of cognition in schizophrenia include the use of tasks from experimental cognitive psychology to examine the integrity of specific cognitive systems and the application of these tasks in noninvasive neuroimaging (e.g., functional magnetic resonance imaging [fMRI]) studies that directly measure the effects of drugs on cognition-related brain activity. These approaches offer many advantages, including the isolation of specific cognitive systems that may be conserved across species; controlling for the confounding effects of generalized performance deficits such as poor motivation, sedation, and so on; and providing a direct translational bridge from studies using animal models of cognition to patient-based research using fMRI. These developments have the potential to transform the early human phases of drug development and streamline the decision making at this critical point in the process. As was the case for the Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative, optimizing the application of cognitive neuroscience to new drug development will require a major commitment by multiple investigators to task development and a thorough psychometric evaluation of both behavioral and neuroimaging measures.",
keywords = "Cognitive enhancement, Cognitive neuroscience, Cognitive psychology, Neuropsychology, Schizophrenia",
author = "Carter, {Cameron S}",
year = "2005",
month = "10",
doi = "10.1093/schbul/sbi046",
language = "English (US)",
volume = "31",
pages = "810--815",
journal = "Schizophrenia Bulletin",
issn = "0586-7614",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia

AU - Carter, Cameron S

PY - 2005/10

Y1 - 2005/10

N2 - New approaches to the measurement of cognition in schizophrenia include the use of tasks from experimental cognitive psychology to examine the integrity of specific cognitive systems and the application of these tasks in noninvasive neuroimaging (e.g., functional magnetic resonance imaging [fMRI]) studies that directly measure the effects of drugs on cognition-related brain activity. These approaches offer many advantages, including the isolation of specific cognitive systems that may be conserved across species; controlling for the confounding effects of generalized performance deficits such as poor motivation, sedation, and so on; and providing a direct translational bridge from studies using animal models of cognition to patient-based research using fMRI. These developments have the potential to transform the early human phases of drug development and streamline the decision making at this critical point in the process. As was the case for the Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative, optimizing the application of cognitive neuroscience to new drug development will require a major commitment by multiple investigators to task development and a thorough psychometric evaluation of both behavioral and neuroimaging measures.

AB - New approaches to the measurement of cognition in schizophrenia include the use of tasks from experimental cognitive psychology to examine the integrity of specific cognitive systems and the application of these tasks in noninvasive neuroimaging (e.g., functional magnetic resonance imaging [fMRI]) studies that directly measure the effects of drugs on cognition-related brain activity. These approaches offer many advantages, including the isolation of specific cognitive systems that may be conserved across species; controlling for the confounding effects of generalized performance deficits such as poor motivation, sedation, and so on; and providing a direct translational bridge from studies using animal models of cognition to patient-based research using fMRI. These developments have the potential to transform the early human phases of drug development and streamline the decision making at this critical point in the process. As was the case for the Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative, optimizing the application of cognitive neuroscience to new drug development will require a major commitment by multiple investigators to task development and a thorough psychometric evaluation of both behavioral and neuroimaging measures.

KW - Cognitive enhancement

KW - Cognitive neuroscience

KW - Cognitive psychology

KW - Neuropsychology

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=26444597019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444597019&partnerID=8YFLogxK

U2 - 10.1093/schbul/sbi046

DO - 10.1093/schbul/sbi046

M3 - Article

VL - 31

SP - 810

EP - 815

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 4

ER -